Mutability and hypermutation antagonize immunoglobulin codon optimality

Joshua J.C. McGrath, Juyeon Park, Chloe A. Troxell, Jordan C. Chervin,Lei Li, Johnathan R. Kent,Siriruk Changrob,Yanbin Fu,Min Huang,Nai-Ying Zheng, G. Dewey Wilbanks, Sean A. Nelson, Jiayi Sun,Giorgio Inghirami,Maria Lucia L. Madariaga,George Georgiou,Patrick C. Wilson

biorxiv(2024)

引用 0|浏览5
暂无评分
摘要
The efficacy of polyclonal antibody responses is inherently linked to paratope diversity, as generated through V(D)J recombination and somatic hypermutation (SHM). These processes arose in early jawed vertebrates; however, little is known about how immunoglobulin diversity, mutability, and hypermutation have evolved in tandem with another more ubiquitous feature of protein-coding DNA – codon optimality. Here, we explore these relationships through analysis of germline IG genes, natural V(D)J repertoires, serum VH usage, and monoclonal antibody (mAb) expression, each through the lens of multiple optimality metrics. Strikingly, proteomic serum IgG sequencing showed that germline IGHV codon optimality positively correlated with VH representation after influenza vaccination, and in vitro , codon deoptimization of mAbs with synonymous amino acid sequences caused consistent expression loss. Germline V genes exhibit a range of codon optimality that is maintained by functionality, and inversely related to mutability. SHM caused a load-dependent deoptimization of IGH VDJ repertoires within human tonsils, bone marrow, and lymph nodes (including SARS-CoV-2-specific clones from mRNA vaccinees), influenza-infected mice, and zebrafish. Comparison of natural mutation profiles to true random suggests the presence of selective pressures that constrain deoptimization. These findings shed light on immunoglobulin evolution, providing unanticipated insights into the antagonistic relationship between variable region diversification, codon optimality, and antibody secretion; ultimately, the need for diversity takes precedence over that for the most efficient expression of the antibody repertoire. ### Competing Interest Statement A patent application was filed on November 11, 2021, relating to anti-SARS-CoV-2 antibodies (including original (unmodified) mAbs used in mAb set 2 of this study) with PCW and SC as inventors (application number PCT/US22/79916). All other authors declare no competing interests.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要